Dr. Errol B. De Souza, Ph.D., serves as NonExecutive Director of Bionomics Limited since February 28, 2008. Dr. De Souza is in research and development concerning the central nervous system . He is the former President and Chief Executive Officer of US biotech companies Archemix Corporationrationration and Synaptic Pharmaceutical Corporationrationration. Dr. De Souza formerly held Senior Management positions at Aventis and its predecessor Hoechst Marion Roussel Pharmaceuticals, Inc. Most recently, he was Senior VicePresident and Site Head of US Drug Innovation and Approval, at Aventis, where he was responsible for the discovery and development of drug candidates through Phase IIa clinical trials for CN S and inflammatory disorders. Prior to Aventis, he was a cofounder and Chief Scientific Officer of Neurocrine Biosciences. Dr. De Souza serves on multiple editorial boards, National Institutes of Health Committees and is a director of several public and private companies.
Age: 58 Director Since 2008
The company has return on total asset (ROA) of (6.29) % which means that it has lost $6.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (13.47) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.09 M in total debt with debt to equity ratio (D/E) of 0.04 which may suggest the company is not taking enough advantage from borrowing. Bionomics Ltd has Current Ratio of 4.42 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Entity SummaryBionomics Limited, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of cancer and disorders of the central nervous system in Australia and France. Bionomics Ltd [BNO] is traded on Australian Securities Exchange in Australia. It is located in Thebarton, SA and employs 11 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| BNO Australian #AU000000BNO5AU
Benchmark S&P 500
Currency: AUD - Australian Dollar
Traded on Australian Securities Exchange
Bionomics Ltd has less than 1.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Bionomics price boundaries
Promote Bionomics and Errol Souza